Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct roles of dopamine receptors in HIV latency reversal in a myeloid cell model.

Frontiers in immunology·2026
Same author

It's Not Rewarding for Mitochondria: Dopamine-Induced Mitochondrial Dysfunction Activates cGAS-STING to Drive IL-6 Secretion in Macrophages.

bioRxiv : the preprint server for biology·2026
Same author

Funding FAIRly: A New Model for Biomedical Research.

Journal of the American Society of Nephrology : JASN·2026
Same author

Opioid-induced immunosuppression of brain myeloid cells in SIV-infected rhesus macaques.

Research square·2025
Same author

Microenvironmental conditions and serum availability alter primary human macrophage NF-κB inflammatory response and function.

Journal of leukocyte biology·2025
Same author

Multi-omic Characterization of HIV Effects at Single Cell Level across Human Brain Regions.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jul 10, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Anti-IgE in severe persistent allergic asthma.

Howard Fox1

  • 1Novartis Horsham Research Centre, Horsham, UK. howard.fox@novartis.com

Respirology (Carlton, Vic.)
|December 13, 2007
PubMed
Summary

Omalizumab, a targeted therapy against IgE, significantly reduces asthma exacerbations in severe persistent asthma patients. This anti-IgE treatment is now recommended for patients meeting Global Initiative for Asthma step 4 criteria.

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Severe persistent asthma significantly impacts healthcare resources.
  • Treatment options for severe asthma remain limited, particularly for patients uncontrolled on standard therapies.
  • Omalizumab targets immunoglobulin E (IgE), offering a novel therapeutic approach.

Purpose of the Study:

  • To evaluate the efficacy of omalizumab in patients with severe persistent asthma (Global Initiative for Asthma step 4).
  • To assess the impact of omalizumab on asthma exacerbations and symptoms in a high-unmet-need population.

Main Methods:

  • A placebo-controlled, double-blind study (INNOVATE) was conducted.
  • Omalizumab was administered as an add-on therapy to existing treatments.
  • Exacerbation rates were analyzed, accounting for pre-study imbalances.

More Related Videos

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Related Experiment Videos

Last Updated: Jul 10, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Main Results:

  • Patients treated with omalizumab experienced a 26.2% reduction in clinically significant asthma exacerbations (P = 0.042).
  • Omalizumab demonstrated low anaphylactic potential.
  • The treatment effectively reduced symptoms and emergency visits.

Conclusions:

  • Omalizumab is a valuable therapeutic option for severe persistent asthma, addressing a significant unmet need.
  • Anti-IgE therapy, specifically omalizumab, is now recommended by the Global Initiative for Asthma for step 4 patients.
  • Omalizumab improves outcomes for patients inadequately controlled by inhaled corticosteroids and long-acting beta agonists.